does tufts cover semaglutide Experts Weigh in on New Generation of Weight Loss Medications Health care spending in R.I.

a sudden drop in energy or refusal to play can signal illness

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

The team can coordinate timing with your pharmacy to ensure you always receive medication at peak freshness

Appetite drops, portions shrink, and meals that once felt normal may suddenly feel overwhelming

Step 4 Timing matters